VRD and Bayern Kapital in €7.4m round for Lophius

To finance the transaction, Bayern Kapital will tap its Bavarian Growth Fund, which was extended by €5.2m after closing.

Lophius will use the funding to accelerate diagnostic developments for tuberculosis using its T cell and immunodiagnostic technologies. It will also invest in commercialising its T-Track diagnostic solution for cytomegalovirus in transplant patients.

Previous funding
In 2008, High-Tech Gründerfonds and Bayern Kapital provided Lophius with €600,000 in seed capital to push forward the company's initial product development. A second round for €1.6m took place in May 2010 with the same investors and S-Refit. These backers all reinvested to provide an additional €1.4m just over a year later in July 2011, and then another €4m in January 2013.

The same three investors participated in another €2m funding round in May 2014 with the goal of increasing market presence and further developing the company's T-Track products. In August 2016, Bayern Kapital was joined by Wolf Biotech and WIC to inject an extra €4.25m specifically for the further funding of the tuberculosis programme.

Company
Founded in 2002 and based in Regensburg, Lophius Biosciences is a biotech company that originally span out of the University of Regensburg. It works on developing T-cell-based diagnostic systems in its laboratory in Regensburg's technology centre Biopark.

The company aims to improve therapy control and personalised treatment of patients in the areas of transplantation medicine, and infectious and autoimmune diseases.

People
Bayern Kapital – Roman Huber (CEO).
Lophius Biosciences – Bernd Merkl (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Healthcare
• Germany
• High-Tech Gründerfonds
• Venture